McKesson Corporation stock (US58155Q1031): Strong FY2026 results and raised guidance

McKesson Corporation, a leading U.S. pharmaceutical distributor, released strong fiscal 2026 results on May 13, 2026, posting full-year revenues of $403.4 billion and adjusted earnings per diluted share of $39.11, exceeding its 12-18% growth targets, Ad-hoc-news.de as of 05/13/2026. In the fourth quarter, revenues increased 6% to $96.3 billion, while adjusted EPS surged 16% to $11.69, beating consensus estimates of $11.56, MarketBeat as of 05/13/2026. Management raised FY2027 adjusted EPS guidance to $43.80-$44.60 and announced a $2.25 billion accelerated share repurchase program.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

McKesson Corporation: core business model

McKesson Corporation operates as one of the largest pharmaceutical distributors in North America, supplying medications, medical supplies, and healthcare services to pharmacies, hospitals, and health systems across the U.S. The company's distribution network handles billions in annual volume, leveraging scale for efficient logistics and supply chain management, according to fiscal 2026 results published on May 13, 2026, Ad-hoc-news.de as of 05/13/2026. Beyond distribution, McKesson provides technology solutions and specialty services that support U.S. healthcare providers in managing costs and patient outcomes.

This integrated model positions McKesson at the center of the U.S. healthcare ecosystem, where it benefits from steady demand for pharmaceuticals amid an aging population and rising chronic disease prevalence. Fiscal 2026 net income reached $4.76 billion, up 45% from FY2025, reflecting operational efficiencies, Simply Wall St as of 05/2026.

Main revenue and product drivers for McKesson Corporation

Fiscal 2026 revenues of $403.4 billion reflect robust growth in the U.S. Pharmaceutical segment, fueled by higher volumes and favorable reimbursement dynamics, according to the company's results published on May 13, 2026, Ad-hoc-news.de as of 05/13/2026. The U.S. Pharmaceutical business, which accounts for the majority of sales, saw contributions from generic drugs, brand-name medications, and increased dispensing volumes at retail pharmacies.

Q4 revenue growth of 6% to $96.3 billion was driven by strong performance in medical-surgical distribution and prescription technology services. Adjusted gross margin stood at 3.60% for the full year, with key drivers including oncology and specialty pharmaceuticals critical to U.S. hospitals, per FY2026 financials reported May 13, 2026, MarketBeat as of 05/13/2026.

Why McKesson Corporation matters for US investors

As a NYSE-listed powerhouse (MCK), McKesson Corporation offers U.S. investors exposure to the resilient $4 trillion-plus U.S. healthcare market, where distribution remains indispensable amid supply chain complexities and regulatory changes. The company's scale provides a competitive moat, serving over 25% of U.S. pharmacies and major health systems, with fiscal 2026 results underscoring its role in stabilizing drug supply during demand surges.

Conclusion

McKesson Corporation's fiscal 2026 results demonstrate operational strength with record revenues of $403.4 billion and EPS growth to $39.11, complemented by upbeat FY2027 guidance of $43.80-$44.60 and a $2.25 billion share repurchase. These developments highlight sustained demand in the U.S. pharmaceutical distribution sector. Investors tracking healthcare equities will monitor execution amid evolving reimbursement policies and supply dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.